About GeneQuantum
An innovative ecosystem builder in the field of bioconjugate therapeutics, pioneering site-specific conjugation technologies to revolutionize ADC therapy.
Company Introduction
GeneQuantum Healthcare (Suzhou) Co., Ltd., headquartered in China, is a global leader in the antibody-drug conjugate (ADC) field. We are distinguished for advancing enzymatic site-specific conjugation technologies that form the foundation of our comprehensive ADC drug development platform.
Our pioneering technologies, iLDC and iGDC, enable precise payload attachment to antibodies, resulting in exceptional product homogeneity, elevated process quality, and enhanced metabolic stability.
Our integrated approach reduces commercial production costs and accelerates global ADC development through collaborative synergy.
Our Vision
To enhance global affordability and expand worldwide access to innovative ADC therapies, fulfilling truly unmet medical needs.
Company Milestones
Aug 2013
Company incorporated in BioBay, Suzhou Industrial Park, China
Jul 2015
Selected as a leading talent for innovation and entrepreneurship in Suzhou
Mar 2017
Completed RMB 40 million Series A financing
Sept 2019
Completed Pre-B round of financing
Dec 2019
GQ1001 Australian clinical trial approved
May 2020
GQ1001 US clinical trial approved
May 2021
Completed hundreds of millions of RMB Series C financing
Apr 2022
GQ1005 and GQ1007 approved for clinical use in Australia
Dec 2022
GQ1005 completed dosing of first subject
Apr 2023
Strategic collaborations with Aimed Bio, Pyramid, WuXi XDC, Asymchem, and others
